Deferred Tax Assets, Valuation Allowance of ARROWHEAD PHARMACEUTICALS, INC. from 30 Sep 2013 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
ARROWHEAD PHARMACEUTICALS, INC. quarterly Deferred Tax Assets, Valuation Allowance in USD history and change rate from 30 Sep 2013 to 30 Sep 2025.
  • ARROWHEAD PHARMACEUTICALS, INC. Deferred Tax Assets, Valuation Allowance for the quarter ending 30 Sep 2025 was $497,543,000, a 11% increase year-over-year.
Source SEC data
View on sec.gov
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Change (%)

ARROWHEAD PHARMACEUTICALS, INC. Quarterly Deferred Tax Assets, Valuation Allowance (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $497,543,000 +$48,676,000 +11% 30 Sep 2025 10-K 25 Nov 2025 2025 FY
Q3 2024 $448,867,000 +$164,241,000 +58% 30 Sep 2024 10-K 25 Nov 2025 2025 FY
Q3 2023 $284,626,000 +$42,232,000 +17% 30 Sep 2023 10-K 26 Nov 2024 2024 FY
Q3 2022 $242,394,000 +$48,139,000 +25% 30 Sep 2022 10-K 29 Nov 2023 2023 FY
Q3 2021 $194,255,000 +$37,651,000 +24% 30 Sep 2021 10-K 28 Nov 2022 2022 FY
Q3 2020 $156,604,000 +$48,371,598 +45% 30 Sep 2020 10-K 22 Nov 2021 2021 FY
Q3 2019 $108,232,402 -$8,642,673 -7.4% 30 Sep 2019 10-K 23 Nov 2020 2020 FY
Q3 2018 $116,875,075 -$19,750,361 -14% 30 Sep 2018 10-K 25 Nov 2019 2019 FY
Q3 2017 $136,625,436 +$7,930,065 +6.2% 30 Sep 2017 10-K 11 Dec 2018 2018 FY
Q3 2016 $128,695,371 +$33,610,326 +35% 30 Sep 2016 10-K 12 Dec 2017 2017 FY
Q3 2015 $95,085,045 +$39,860,243 +72% 30 Sep 2015 10-K 14 Dec 2016 2016 FY
Q3 2014 $55,224,802 +$107,438,892 30 Sep 2014 10-K 14 Dec 2015 2015 FY
Q3 2013 $52,214,090 30 Sep 2013 10-K 25 Nov 2014 2014 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.